ASCO: American Society of Clinical Oncology

With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring adjuvant immunotherapy for patients with negative results for disease following surgery.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

Flatiron Telescope uses AI and transparent SQL to turn real-world evidence into quick turnaround oncology research and FDA-ready analytics.

Armored DLL3 CAR T-cell therapy from Legend Biotech/Novartis shows early responses in small cell lung cancer and neuroendocrine tumors, according to presentation at ASCO.

Investigators described the combinations as a potential new standard of care in second-line HR+/HER2− advanced breast cancer.

Posttransplant revumenib maintenance shows promising survival and low relapse in high-risk AML subtypes, with manageable thrombocytopenia; the randomized MenTain trial is planned.

McKesson and The US Oncology Network find EOM attribution often mislabels cancer episodes—especially oral therapy—threatening value-based care accuracy and accountability.

Real-world ASCO data link GLP-1 drugs to markedly longer survival across common cancers, raising new questions on mechanism and trials.

LINKER-AL2 shows linvoseltamab delivers rapid, deep responses in relapsed AL amyloidosis, addressing major unmet need with off-the-shelf access and a manageable safety profile.

I-SPY 2.2 of rilvegostomig plus trastuzumab deruxtecan in breast cancer treatment cut chemo use while exposing access issues and disparities.

The lead investigator for SUCCESSOR-2 discusses the potency of a potential successor to pomalidomide in treatment of multiple myeloma, with survival outcomes that rival CAR T-cell therapy.

Nancy Lin, MD, explores MMAI validation needs, turnaround advantages, equity implications, and how payers should approach AI-based diagnostics.

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy.

Nancy Lin, MD, explains how an AI model compares with genomic classifiers in HR+/HER2- early breast cancer, with implications for cost and access.

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option.

By controlling for ovarian suppression, OPTIMA shows Prosigna works equally well in pre and postmenopausal high-risk early breast cancer.

Remote therapeutic monitoring with ePROs powered by AI cuts hospitalizations and boosts therapy time—now a key oncology leader promotes guidelines and reimbursement to make it standard of care.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.

OPTIMA trial data show genomic testing helps many patients with high‑risk breast cancer skip chemotherapy safely and start endocrine therapy sooner.

Canopy remote therapeutic monitoring with ePROs cuts hospitalizations and extends time to discontinuation in metastatic cancer, saving millions.

Chemotherapy decisions for young women with HR+ breast cancer and low recurrence scores reveal testing disparities that health systems must address.

An AI-driven review of oncology trials reveals that diversity progress over 30 years is largely an illusion driven by Asian enrollment growth.

Longer-term data support pimicotinib as an effective, well-tolerated option for a rare benign tumor that can cause significant joint disability.

From cardiovascular risk to missed toxicity grading, Igor Puzanov, MD, MSCI, outlines what is failing in checkpoint inhibitor toxicity management.

ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs with fewer visits.

Data presented at ASCO support wider use of prophylactic therapy to prevent cytokine release syndrome as efforts expand to promote bispecifics in treatment of multiple myeloma.

Data confirm the use of daratumumab, bortezomib, lenalidomide, and dexamethasone as the standard of care in newly diagnosed multiple myeloma.

ADC targeting both PSMA and STEAP1 with a topoisomerase payload showed a 15-month PFS signal in heavily pretreated prostate cancer—far above historical chemotherapy benchmarks.

Updated SUNMO phase 3 data show Mosun-Pola cuts progression risk by 62% vs R-GemOx, with a 75% ORR and 61% CR rate in second-line R/R LBCL at 28-month follow-up.